Pluristyx, Inc. Email Format
Biotechnology ResearchWashington, United States11-50 Employees
Pluristyx, Inc. is a biotechnology research company headquartered in Seattle, Washington, with 11-50 employees and operating from two North American sites. It provides iPSC-based products and services to support early-stage product development. In July 2023, Pluristyx merged with panCELLa, combining stem cell research and gene-editing capabilities to form an expanded platform. The merged entity aims to become a global provider of clinical-grade, genetically modified, off-the-shelf induced pluripotent stem cells, designed to accelerate progression to clinical development and commercialization. Recent activity includes a May 2026 distribution agreement with Qkine, the February 2026 PluriForm-GFP-3D Transfection Kit launch with Solesis and integration for transfection, a December 2025 collaboration with Mytos and Aspen to automate GMP manufacturing, and a November 2025 partnership with BreakthroughT1D to develop immune-cloaked, safety-switch-enabled allogeneic cell lines for Type 1 Diabetes therapies.